Baron AD - Search Results

1

The Sweet syndrome during therapy with granulocyte colony-stimulating factor.

Park JW, Mehrotra B, Barnett BO, Baron AD, Venook AP. Park JW, et al. Among authors: baron ad. Ann Intern Med. 1992 Jun 15;116(12 Pt 1):996-8. doi: 10.7326/0003-4819-116-12-996. Ann Intern Med. 1992. PMID: 1375012 No abstract available.

2

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.

Small EJ, Baron AD, Fippin L, Apodaca D. Small EJ, et al. Among authors: baron ad. J Urol. 1997 Apr;157(4):1204-7. J Urol. 1997. PMID: 9120902 Clinical Trial.

3

Pseudomonas aeruginosa bronchopulmonary infection in late human immunodeficiency virus disease.

Baron AD, Hollander H. Baron AD, et al. Am Rev Respir Dis. 1993 Oct;148(4 Pt 1):992-6. doi: 10.1164/ajrccm/148.4_Pt_1.992. Am Rev Respir Dis. 1993. PMID: 8214956

4

Ultradian variations of chromogranin A in humans.

Takiyyuddin MA, Neumann HP, Cervenka JH, Kennedy B, Dinh TQ, Ziegler MG, Baron AD, O'Connor DT. Takiyyuddin MA, et al. Among authors: baron ad. Am J Physiol. 1991 Oct;261(4 Pt 2):R939-44. doi: 10.1152/ajpregu.1991.261.4.R939. Am J Physiol. 1991. PMID: 1681748

5

Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies.

Takiyyuddin MA, Baron AD, Cervenka JH, Barbosa JA, Neumann HP, Parmer RJ, Sullivan PA, O'Connor DT. Takiyyuddin MA, et al. Among authors: baron ad. J Clin Endocrinol Metab. 1991 Mar;72(3):616-22. doi: 10.1210/jcem-72-3-616. J Clin Endocrinol Metab. 1991. PMID: 1671783

6

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD. Fineman MS, et al. Among authors: baron ad. Diabetes Care. 2003 Aug;26(8):2370-7. doi: 10.2337/diacare.26.8.2370. Diabetes Care. 2003. PMID: 12882864 Clinical Trial.

7

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Kolterman OG, et al. Among authors: baron ad. J Clin Endocrinol Metab. 2003 Jul;88(7):3082-9. doi: 10.1210/jc.2002-021545. J Clin Endocrinol Metab. 2003. PMID: 12843147 Clinical Trial.

8

Response to Bell: industry perspective.

Baron AD. Baron AD. Diabetes Care. 2001 Apr;24(4):769-70. doi: 10.2337/diacare.24.4.769. Diabetes Care. 2001. PMID: 11315845 No abstract available.

9

Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms.

Trevaskis JL, Coffey T, Cole R, Lei C, Wittmer C, Walsh B, Weyer C, Koda J, Baron AD, Parkes DG, Roth JD. Trevaskis JL, et al. Among authors: baron ad. Endocrinology. 2008 Nov;149(11):5679-87. doi: 10.1210/en.2008-0770. Epub 2008 Jul 31. Endocrinology. 2008. PMID: 18669592

10

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.

Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Fineman MS, et al. Among authors: baron ad. Diabetes Metab Res Rev. 2004 Sep-Oct;20(5):411-7. doi: 10.1002/dmrr.499. Diabetes Metab Res Rev. 2004. PMID: 15343588 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters